Roche and AZ's Lynparza doubled the PFS in patients with BRCA-Mutated Metastatic pancreatic cancer
Updated: Jun 3, 2019
Merck and AstraZeneca have published the results of Phase 3 POLO trial evaluating Lymparza tablets in the patients suffering from germline BRCA-Mutated Metastatic Pancreatic Cancer. The therapy is indicated in the first line.
The results were published in the ASCO shown that the Lynparza has significant improvement in the progression-free survival compared to placebo. Median PFS was 7.4 months is Lynparza arm compared to 3.8 months on the placebo arm. At six months, patients on Lynparza are free from progression compared to the patients on placebo.
Common adverse events include the fatigue, nausea abdominal pain, and constipation.
The product has not yet approved the United States Food and Drug Administration.